asianprimenews
GeneralPublic Interest

Why CML Isn’t a Solved Disease—And What Patients in India Need to Know

Over the past two decades, Chronic Myeloid Leukemia (CML) has undergone a transformation—from being a life-threatening condition to one that can be controlled with oral medication. Although survival rates have improved significantly, the idea of CML as a ‘manageable’ disease is now being questioned. Clinicians and patients alike are recognizing that the existing standard of care does not address the full picture—especially for India’s younger patient population, whose needs go far beyond survival.

Dr Subhaprakash Sanyal Director of Haematology and BMT Services, Fortis Hospital, Mumbai, said, “There’s a common belief that starting treatment for CML means the journey is simple, but that isn’t the case. Many patients struggle to reach their treatment milestones as expected, and a significant portion need to change or stop their medication due to side effects or intolerance. In fact, about 30 to 40% discontinue their initial therapy within five years, highlighting that the standard approach doesn’t work for everyone.”

CML disproportionately affects younger adults in India, where the median age of diagnosis is between 35 and 40 years—much younger than the average age of 50–60 in Western countries. At this life stage, patients are often building careers, supporting families, and planning long-term futures. In this context, treatment is no longer just about survival—it’s about maintaining energy, emotional well-being, professional productivity, and daily independence.

Historically, the primary treatment goal in CML was achieving Major Molecular Response (MMR). But over the years, these goals have evolved. Today, physicians aim for deeper responses, particularly Deep Molecular Response (DMR). Achieving DMR paves the way for Treatment-Free Remission (TFR), where patients can potentially stop therapy altogether and remain in remission under medical supervision.

These advanced milestones are particularly relevant to newly diagnosed patients, as reaching DMR within the first two years greatly improves the likelihood of achieving TFR down the line.

Why So Many Patients Fall Short
Despite clear treatment goals, a significant proportion fail to achieve MMR within the first year, and even fewer reach DMR by year two. One of the primary reasons is the impact of persistent, low-grade side effects—such as fatigue, joint pain, and gastrointestinal issues—which patients often tolerate silently but which meaningfully reduce their quality of life.
These side effects also drive nonadherence, dose modifications, and ultimately treatment discontinuation. In fact, treatment intolerance is the leading cause of therapy discontinuation in the first two years of CML management. Adding to the complexity, current treatments—particularly ATP-competitive tyrosine kinase inhibitors (TKIs)—can affect not just the intended target but also unrelated biological pathways, causing off-target toxicity. This often leads to therapy switches, a strategy that increases both clinical and emotional burden without necessarily resolving the issue.

A recent Indian analysis noted that nearly all CML patients report some form of low-grade side effect, many of which disrupt work and personal life but don’t qualify for hospitalization. As a result, patients feel caught in a difficult balance—managing a chronic illness while enduring ongoing discomfort or disruptions.

The Case for Better-Tolerated, More Effective Therapies
As the treatment landscape evolves, the need for therapies that not only offer deeper molecular responses but also better tolerability is becoming increasingly clear. Emerging therapies with novel mechanisms of action have begun to change the paradigm by offering comparable—or even superior—efficacy alongside fewer adverse events and lower discontinuation rates.

In one international phase III trial, a newer therapy demonstrated a 74.1% MMR rate at 96 weeks, significantly higher than the 52.0% achieved by older therapies. It also showed a 54% lower risk of treatment discontinuation due to side effects, while nearly half of patients achieved MR4 and 30.9% achieved MR4.5, the deepest levels of response. These findings suggest that treatment no longer needs to be a trade-off between efficacy and day-to-day functioning.

This shift is particularly important in the Indian context, where younger patients face the possibility of decades-long treatment. For them, the ability to tolerate therapy comfortably while still achieving long-term disease control is not a luxury—it’s a necessity.

The Importance of Proactive Conversations
Many patients continue older treatments unaware that newer, more tolerable options exist. This makes open doctor–patient conversations crucial—especially early in treatment. Patients should understand their goals, like DMR or TFR, and how their therapy aligns with them. Discussing side effects, lifestyle impact, and alternatives helps ensure care is not just effective, but sustainable and suited to their lives.

While CML outcomes have improved, challenges remain—particularly for India’s younger patients. As treatment goals expand and better options emerge, the focus must shift from merely managing the disease to helping patients live well. The future of CML care lies in deeper responses, better tolerability, and enabling life beyond medication.

Share

Related posts

Yarn Manufacturer Sanathan Textiles refiles DRHP to raise Rs 800 crs Mumbai-based Sanathan Textiles, one of the few companies in India having a presence across the polyester, cotton, and technical textile sectors has refiled its draft red herring prospectus (DRHP) with the market regulator Securities and Exchange Board of India (SEBI) to raise Rs 800 crore through its Initial Public Offering (IPO). The IPO with a face value of Rs 10 comprises of fresh issue of equity shares aggregating up to Rs 500 crore and an offer for sale of up to Rs 300 crore by Promoters and Promoter Group. The offer for sale consists of the sale of equity shares of up to Rs 61.87 crore by Paresh Vrajlal Dattani, Rs 69.35 crore by Ajay Vallabhdas Dattani, Rs 71.12 crore by Anilkumar Vrajdas Dattani, Rs 74.37 crore by Dinesh Vrajdas Dattani, Rs 50 Lakh by Vajubhai Investments Private Limited, Rs 50 Lakh by Vallabhdas Dattani HUF, Rs 4.5 crore by Sonali Ajaykumar Dattani, Rs 50 Lakh by Dattani Dineshkumar Vrajdas HUF, Rs 7 crore by Beena Paresh Dattani, Rs 3.5 crore by Anilkumar Vrajdas Dattani HUF, Rs 6 crore by Paresh Kumar V Dattani HUF, Rs 25 Lakh by Jayshree Anilkumar Dattani, Rs 2.5 Lakh by Ajay Kumar V Dattani HUF, and Rs 50 Lakh by Vallabhdas Dattani. Additionally, the company, in consultation with the lead bankers to the issue may consider a pre-IPO placement of equity shares aggregating up to Rs 100 crore. Proceeds from the fresh issue of shares will be used to the extent of Rs 175 crore for repayment or pre-payment, in full or in part, of certain of its outstanding borrowings availed by the Company, Rs 210 crore for investment in its subsidiary viz. Sanathan Polycot Private Limited for funding its long-term working capital requirements besides general corporate purposes. Sanathan Textiles operates three distinct yarn business divisions: Polyester yarns, cotton yarns, and yarns for technical textiles and industrial applications. These divisions are currently managed under a single corporate entity. The company specializes in value-added yarn products, including dope-dyed, superfine/micro, functional, industrial, and technical yarns, as well as cationic dyeable and specialty yarns. These products result from extensive in-house research efforts. For the nine months ended December 31, 2023, value added products sold as a % of Total products sold stood at 48.50% which is significantly higher than 41.97% in Fiscal 2021. Additionally, in FY22 it has also started its sustainable textile initiative under the brand Sanathan Rivero where it recycles waste plastic bottles and converts them into yarns for fabrics The Products are manufactured at the Silvassa facility, which has grown its capacity significantly to 223750 metric tonnes per annum (MTPA) as of December 31, 2023, from 213,725 metric tonnes per annum (MTPA) in Fiscal 2021 at the Silvassa facility across the three yarn divisions. Recently it has acquired 80 acres of land in Wazirabad, Punjab where it is at an advanced stage to commission a greenfield facility that will manufacture Polyester yarn products and will increase its capacity by 550 tonnes per day to 1500 tonnes per day. As of December 31, 2023, Sanathan Textiles had developed over 2,800 active varieties of yarn products and maintained more than 30,000 stock-keeping units (SKUs). The company’s manufacturing capabilities encompass a diversified product range of over 14,000 yarn varieties and more than 190,000 SKUs, serving various end uses. Over the years, the Mumbai-based company has established long-standing relationships with consumer brands such as Welspun India Limited, Valson Industries Limited, G.M. Fabrics Private Limited, and many more. In terms of customer reach, the company served 1,466 customers during the nine months ended December 31, 2023, and 1,684 customers during Fiscal 2023. Sanathan Textiles has a strong international presence, exporting its products to 26 countries during the nine months ended December 31, 2023, and 29 countries throughout Fiscal 2023. It has a network of over 902 distributors across seven countries, including India, Argentina, Singapore, and Portugal. The share of Domestic operations as a % of revenue from operations have increased from 87.39% in Fiscal 2021 to 95.60% for the nine months ended December 31, 2023, bringing down the share of exports as a % of revenue from operations to 4.40% for the nine months ended December 31, 2023 from 12.61% in Fiscal 2021. The companies consolidated revenue from operations during the fiscal year 2023 increased 4.52% to Rs 3,329.21 crore from Rs 3,185.32 crore in the previous year. Profit after tax was Rs 152.74 crore for the financial year 2023. For the nine months ended December 31, 2023, revenue from operations stood at Rs 2201.37 crore, and profit after tax stood at Rs 81.59 crore. Its total borrowings reduced from ₹ 541.16 cr on April 1, 2021 to ₹ 374. 01 cr on February 29, 2024. Dam Capital Advisors Limited and ICICI Securities Limited are the book-running lead managers and KFin Technologies Limited is the registrar of the issue. The equity shares are proposed to be listed on BSE and NSE.

asianprimenews

Medanta Q2 results: Net Profit up 46% to Rs 125 crore

asianprimenews

Malaysia Airlines Expands Bonus Side Trip Programme with New Domestic and Regional Destinations

asianprimenews